• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services


  • Print
  • Share
  • E-mail

Enbrel (etanercept) May 2000

Post-marketing reports of adverse events of rare cases of nervous system disorders including demyelinating disorders such as multiple sclerosis, myelitis, and optic neuritis have been reported in patients with rheumatoid arthritis who have received Enbrel therapy.

[October 10, 2000 - Letter - Immunex Corp./Wyeth-Ayerst Pharmaceuticals]


Health professionals are asked to help reduce difficulties experienced by some patients with self-administration of Enbrel. The main difficulty is in penetrating the vial stopper with the needle on the supplied syringe, resulting in bent and otherwise damaged needles.

[May 12, 2000 - Letter - Immunex Corp./Wyeth-Ayerst Pharmaceuticals]